Platelets adhering to artificial or biologic surfaces have been implicated in the pathogenesis of catheter infections or endocarditis; however, the ligands involved in Staphylococcus aureusinteraction.with adherent platelets remain incompletely understood. Radiolabeled S. aureusCowan 1 were incubated with purified platelets adherent to polymethylmethacrylate (PMMA) coverslips and washed, and adhesion was determined. Platelets promoted adhesion of S. aureus --30-fold compared with adhesion to albumin-PMMA. In the presence of both plasma (1% vol/vol) and platelets, adhesion was extensively promoted, with 30% (of inoculated) S. aureusadherent (150-fold increase). Platelet pretreatment with anti-GPIIb/IIIa monoclonal antibodies or inhibitors of platelet activation decreased plasma-enhanced adhesion, suggesting a role of platelet activation in S. aureus adhesion. Plasma-enhanced adhesion was sensitive to thrombin antagonists, proteinase inhibitors, heparin, or antifibrinogen antibodies, indicating that fibrinogen/fibrin is necessary for bridging between adherent platelets and S. aureus. In conclusion, S. aureusadhesion to immobilized platelets may playa role in the pathogenesis of invasive bloodstream infections or endocarditis.
and thrombus formation on the catheter has been identified as a major risk factor for device infection [4] .
S. aureus is also a common pathogen in acute infective endocarditis, causing 20%-30% of episodes [5) . As with catheter-associated infection, the first step in infective endocarditis is bacterial adhesion to valvular tissue via specific interactions between microorganisms and host ligands. While intact heart valves are occasionally involved in infective endocarditis, damage to the valvular endocardium, exposure of the subendothelial matrix, and deposition of fibrin and platelets on the valvular surface (nonbacterial thrombotic endocarditis [6] ) are much more frequent antecedent events in the development ofinfection (7) . As in device-related infections, a role for extracellular matrix proteins in the pathogenesis of endocarditis has been suggested [8] .
Several investigators have studied the interaction of platelets with a variety of microorganisms associated with endocarditis or catheter infection, such as staphylococci [9, 10] or streptococci [11] ; this interaction results in platelet activation, secretion, and irreversible platelet aggregation. More recently, it has been shown by flow cytometry that both viridans streptococci [12] and S. aureus [13] bind to platelets even in the absence of plasma proteins. However, these studies were all done with suspended platelets, which does not necessarily reflect the in vivo situation of staphylococcal adhesion to immobilized, activated platelets.
Platelets undergo extensive changes after adhesion, including activation of surface receptors, release of proteins stored in granules, and binding of ligands to platelet membrane receptors (reviewed in [14] ). Several authors have studied the role of platelets on the promotion of bacterial adhe-sion to surfaces. Scheid et al. [15] reported that platelets incorporated into in vitro-formed fibrin matrices significantly promoted adhesion of streptococci, and Chugh et al. [16] showed more recently that adhesion of S. epidermidis to fibrin matrices is increased in the presence of platelets. In contrast, Cheung and Fischetti [17] reported that platelet-rich plasma preincubated with urethane catheter tubing did not promote adhesion of S. aureus significantly compared with platelet-free plasma. A limitation ofthese studies is that they were done with platelet-plasma mixtures. Therefore, a more precise assessment of the respective roles of platelets and plasma factors in the promotion of S. aureus adhesion to surfaces warrants a separate examination of the different interacting components in a purified form.
The aim ofthis study was to delineate more clearly the role of purified adherent platelets in staphylococcal adhesion and the potential effect of soluble plasma proteins on this interaction. We hypothesized that certain plasma proteins may interact with both specific receptors on platelet surfaces such as platelet membrane glycoproteins and staphylococcal adhesins by forming bridges between S. aureus and plateletcoated surfaces.
Materials and Methods
Proteins. Whole, fresh human plasma was prepared from the blood of>6 healthy volunteers by centrifugating ACD (citric acid, final concentration,S mM; sodium citrate, 10 mM; and dextrose, IS mM)-anticoagulated blood for 15 min at 1500 g; plasma was pooled, aliquoted, and stored at -70°C until further use. In some experiments, heparin (15 USP units/rnl, of blood; Upjohn, Kalamazoo, MI) was used as the anticoagulant instead of ACD. Control experiments revealed that similar results were obtained in adhesion assays using different batches of plasma (data not shown). In some experiments, whole plasma was treated by dialyzing against 250 vol of PBS using Spectra/Per tubing (molecular-weight cutoff, 12,000-14,000; Spectrum, Los Angeles) overnight at 4°C, by filtering with 0.2-JLm GS filters (Millipore, Bedford, MA), by heating at 56°C for 30 min in a water bath, or by clotting after supplementation of Ca?" at 3rC and centrifuging at 2000 g. Fibronectin, fibrinogen, and thrombospondin were purified as described [18] . Vitronectin was purified using heparin affinity chromatography [19] . Purity of all proteins was checked by SDS-PAGE with and without reduction.
Antibodies and inhibitors. The monoclonal antibodies (MAbs) AP I, directed against the platelet membrane glycoprotein GPIb [20] , and AP 2, directed against the GPIIb/IIIa complex [21] , were provided by T. Kunicki, Blood Center of Southeastern Wisconsin, Milwaukee. Both antibodies are of IgG I subclass. The MAbs IOE5, 7E3, 6D I, and 6F I were provided by B. Coller, State University of New York at Stony Brook. Antibodies IOE5 and 7E3 (IgG I) are directed against GPIIb/lIIa [22] , antibody 6DI (IgGl) against GPIb [23] , and 6FI (IgGI) against GPIa/IIa [24] . The MAb LM 609, directed against a human melanoma vitronectin receptor [25] , was provided by D.
Cheresh, Research Institute of Scripps Clinic, La Jolla, CA. The MAb OKM 5 (directed against GPIV [26] ) was provided by P. Rao, Ortho Diagnostics, Raritan, NJ. The MAb TM 60, directed against GPlb (IgG2a) [27] , was provided by N. Yamamoto, Tokyo Metropolitan Institute of Medical Sciences. Control MAbs of the IgG I and IgG2a subclass were purchased from Sigma (St. Louis). Purified MAbs were used at a working concentration of 20 JLg/mL according to data showing effective blocking of the respective ligand or ligand-induced platelet aggregation using these or lower concentrations [22] [23] [24] . Final working dilutions of antibodies API and AP2 (stock solution in ascites fluid) were 1:50. Polyclonal sheep anti-human fibrinogen antibodies were purchased from ICN Immunobiologicals (Lisle, IL), goat anti-human fibrinogen-lgG F(ab')2 fragments from Organon Teknika Cappel (West Chester, PA), and rabbit preimmune IgG from Sigma. The working concentration of these antibodies was 100 JLg/mL. Rabbit anti-thrombospondin antiserum and rabbit anti-fibronectin antiserum were prepared locally and were specific as judged by immunoblotting of partially purified preparations ofantigens; the antibody titers (halfmaximal adsorption in ELISA) were I: 16,000 and I:650, respectively. The working dilution of both immune antisera and of preimmune rabbit antiserum was 1:50.
In some experiments, adhesion assays were supplemented with the specific thrombin antagonist n-phenylalanyl-prolyl-arginyl chloromethyl ketone (PPACK; Calbiochem, La Jolla,CA) [28] or with the serine proteinase inhibitor phenylmethylsulfonyl fluoride (PMSF; Sigma) [29] .
Bacterial growth and labeling. S. aureus Cowan I, a stable, protein A-rich laboratory strain binding fibronectin, fibrinogen, and thrombospondin, was used in all experiments. Working cultures were maintained on Mueller-Hinton agar plates. For each experiment, bacteria were grown from a fresh overnight culture in Mueller-Hinton broth and radiolabeled as previously described [30] by incubating 2 X 10 7 cfu/ml. from an overnight culture with [3H]thymidine (NEN Research Products, Boston) at 50 JLCi for 3 h at 37°C. After incubation, bacteria were washed twice in PBS, vigorously vortexed for 30 s, and resuspended at a concentration of ,...., I X.I 0 8 cfu/ml, in Tyrode's buffer. Microscopic observation of both viable and gram-stained bacteria revealed that >95% of the cells were single cells. Specific activities were determined in each experiment by counting counts per minute (cpm) and colony-forming units (cfu) of a sample of the bacterial suspension and were found to be 15,000-25,000 cpm/rnin for I X 10 5 bacteria. Platelets. Platelets were purified as previously described [31] . Blood samples (10 mL) were collected in polypropylene tubes containing ACD and mixed by gentle inversion. Plateletrich plasma was prepared by centrifuging whole blood at 180 g for 10 min. Platelet-rich plasma was removed, and platelets were separated from plasma proteins by passage through an A-50 column (Bio-Rad, Richmond, CA) having a 40-mL total bed volume. The column was equilibrated with calcium-free Tyrode's buffer, pH 7.3 (136 nMNaCl, 2.7 nMKCI, 3.3 mMNaH 2P04 , 10.5 mM HEPES salt, 4.45 mMHEPES free acid, 2 mM MgCI 2 , Ig/L dextrose, and I giL bovine serum albumin [BSA] ). The platelet number was determined with a Coulter counter (Coulter Electronics, Hialeah, FL), and the final concentration lID 1993;167 (February) was adjusted to 1.5 X 10 8 platelets/ml.. In some experiments, prostaglandin E J (PGE J , 40 ng/rnl.; Sigma) was added during collection of whole blood and equilibration of the column to prevent platelet activation.
Assay for in vitro staphylococcal adhesion to platelet-coated surfaces. Polymethylmethacrylate (PMMA), a material widely used for implants, was selected as the solid phase in the S. aureus adhesion assay: PMMA has been found to be well suited for parallel evaluation of the samples using a quantitative adhesion assay, for video-enhanced phase contrast microscopy, and for scanning electron microscopy (SEM). Moreover, the use of PMMA in S. aureus adhesion assays has been correlated with clinical disease [30, [32] [33] [34] [35] . The previously described assay [30] was modified as follows: PMMA coverslips (0.8 X 0.8 mrn), a gift from P. Vaudaux, University of Geneva, were cleaned in 100% ethanol and sterilized by heating (120°C, 10 min). In some experiments, coverslips were coated with poly-i-lysine (PLL; Sigma) at 0.1 mg/ml, for 60 min at ambient temperature, a polyamino acid widely used to nonspecifically promote cell adhesion to solid substrates [36] . The platelet suspension, 100 ,uL containing 150,000 platelets/,uL, was overlaid onto PMMA coverslips for 15 min at 37°C. The fluid was removed by gentle suction and immediately replaced by 100,uL of Tyrode's buffer without BSA; care was taken that surfaces did not dry. In control experiments, the number of platelets adherent to PMMA was determined by counting the number of platelets in "l0 visual fields (each field of a surface of 86 X 110,um) using video-enhanced interference-based contrast microscopy (see below) of glutaraldehyde-fixed adherent platelets and was found to be 10,100 ± 1600 platelets/ram? (mean ± SD, n = 3). In some experiments, the washing buffer was supplemented with recombinant human a-thrombin (1 IU /rnl.), provided by J. Fenton II (New York State Department of Health, Albany).
For the adhesion assay, the solution contained radiolabeled S. aureus in Tyrode's buffer (without BSA) supplemented with Ca2+ (1 mM) and 0.1 %dextrose (total volume, 0.5 mL). In addition, all samples were incubated in the presence of human albumin (HA, 0.5% wt/vol; Sigma) to block adhesion of S. aureus in the absence of specific ligands [2, 30, 32, 35] . In some experiments, S. aureus were preincubated for 5 min with human plasma (1 % vol/vol in Tyrode's buffer supplemented with HA [0.5%] and Ca 2 + [I mM]) and then the bacteria were added to the washed, platelet-coated coverslips for incubation. Incubation continued at 3rC in a shaker bath, usually for 60 min. A final concentration of I % plasma was found to be optimal for promoting adhesion without formation of a visible clot in the test tube in Ca2+-containing conditions. After being incubated, coverslips were washed twice in Tyrode's buffer and transferred into scintillation vials (Research Product International, Mt. Prospect, IL) for determination of cpm. Adhesion was calculated using the following formula: Adhesion (%) = [cpm (adherent)/ cpm (inoculated)] X 100. In some experiments, adhesion was expressed as percentage ofadhesion in the test sample compared with adhesion in a parallel control sample.
Optimal inoculum size was determined in preliminary studies. Various dilutions ofS. aureus Cowan 1 were incubated with platelet-coated PMMA in the presence of 1%plasma. The number of adhering S. aureus continued to increase even with large inoculum sizes (> I X 10 9 cfu/rnl., figure I ) without showing clear saturation; however, the percentage of adherent microorganisms was found to be highest (32.2%) with an inoculum of 3.3 X 10 6 cfu/rnl. and decreased to 53% with an inoculum of 3.3 X 10 9 cfu/rnl., The lack of saturation was probably due to S.
aureus-S. aureus interactions (clumping), as this was visualized
directly. Subsequently, all experiments were done using "-'4 X 10 6 cfu/ml, except for samples prepared for electron microscopy.
Absence of other adhesion-promoting factors that potentially contaminated the platelet suspension was checked in a control adhesion assay. After gel purification of platelets, a sample of the suspension was centrifuged at 2000 g for 10 min. PMMA coverslips were coated in parallel either with the suspension containing gel-purified platelets or with the platelet-free supernatant, and adhesion with S. aureus was determined. Whereas the platelet-containing suspension promoted subsequent S. aureus adhesion in the presence of plasma (mean adhesion ± SE: eluded, these do not contribute significantly to the platelet-induced adhesion promotion observed in the assay.
Evaluation ofthe activity ofpurified plasma components to promote S. aureus adhesion to platelet-coated surfaces. To more closely delineate the factor(s) contained in plasma that promotes adhesion to platelet-coated surfaces, the incubation solution was supplemented with purified proteins instead of whole plasma. The final concentration chosen for fibrinogen was 80 g/mL, a concentration about equal to 2%plasma. Fibronectin, thrombospondin, or vitronectin was used in the same concentration. In some experiments, plasma fractions prepared according to Cohn et al. [37] were added at a final concentration of 50 g/mL. As another approach to determine the role of plasmacontained fibrinogen or fibronectin in platelet-So aureus interaction, solutions containing 1% plasma were incubated prior to addition of S. aureus and platelet-coated PMMA with either anti-human fibrinogen IgG, anti-human fibrinogen IgG F(ab')2 fragments, or rabbit control preimmune IgG, each in a final concentration of 100~jmL. Thereafter, coverslips were added, and inhibition of staphylococcal adhesion by antibodies was determined according to the formula above.
Microscopic observations. S. aureus Cowan 1 was grown to exponential phase, and PMMA coverslips were coated with platelets as described above and incubated with S. aureus for 60 min at 37°C. Preliminary experiments showed that for microscopic observation the inoculum had to be increased to 1-2 X 10 8 cfu/ml. to visualize adherent microorganisms, a concentration still below saturation (figure 1). After incubation, samples were washed twice and fixed in 0.1 M HEPES-buffered 1%glu-taraldehyde. Specimens were dehydrated through a graded series of alcohols to absolute alcohol, dried by the critical-point procedure using liquid CO 2, gold-coated, and stored until examined by SEM (Hitachi S570; Mountain View, CA) [38] . For light microscopy experiments, specimens were prepared and fixed as described above, examined using a Nikon (Garden City, NY) Diaphot light microscope modified for asymmetric interference contrast (AIC), and visualized with a high-resolution Newvicon video camera (PAGE-MTI, Michigan City, IN) [38] . Numbers ofadherent platelets were determined by counting 10 visual fields (each field of a surface of 86 X 110~m)jcoverslip.
Statistical analysis.
Results are mean ± SE of duplicate experiments done independently at least twice with platelets from different donors. Data of S. aureus adhesion to platelets were analyzed by using the nonparametric Mann-Whitney rank tests for unrelated rankable scores. Multivariate analysis of the effect of plasma pretreatment or substitution with plasma proteins was done using single factor factorial analysis of variance and Fisher's protected least significant difference [39] .
Results
Adhesion ofS. aureus to albumin-coated surfaces. S. aureus Cowan 1 was used to develop and validate analysis of staphylococcal adhesion to PMMA coverslips. We controlled the assay by incubating radiolabeled S. aureus with uncoated coverslips in the presence of 0.5% HA and confirmed previous observations using this adhesion assay [30, 32, 35] ; specifically, adhesion to albumin-coated PMMA was very low (0.2% ± 0.1 %, mean ± SE, n = 3). Parallel samples were analyzed using SEM and revealed a surface with a virtual absence of microorganisms (figure 2A). In addition to albumin, serum and plasma block nonspecific adhesion ofS. aureus to polymers [2] , and we found that adding human plasma (1% vol/vol) to the incubation solution increased adhesion to 1.0% ± 0.3% (mean ± SE, n = 7). Thus, because staphylococcal adhesion to uncoated PMMA is relatively low in the presence both ofHA and plasma, the conditions in this assay allowed a specific analysis ofadhesion-promoting cellular elements such as platelets in the interaction of S. aureus with PMMA surfaces. All subsequent experiments were done in the presence of 0.5% HA.
Role of platelets and plasma proteins in the mediation of adhesion ofS. aureus to PMMA. To determine the effect of adherent platelets on staphylococcal adhesion, coverslips were precoated with purified human platelets, then washed and incubated with S. aureus for 60 min. The presence of platelets adherent to PMMA promoted adhesion 28-fold compared with albumin-coated PMMA (5.6% ± 4.4% vs. 0.2% ± 0.1 %, mean adhesion ± SE, n = 5; P = .0253, MannWhitney test). SEM of platelet-coated surfaces showed that microorganisms adhered both to the platelet membranes and to the substrate (figure 2B). Whole human plasma (l % vol/ vol) added to the assay containing S. aureus and plateletcoated coverslips increased adhesion l Sl-fold compared with albumin-coated PMMA (30.2% ± 5.3% vs. 0.2%, n = 14; P = .0081, Mann-Whitney test); comparison of this result with that from platelet-free and plasma-free conditions showed a 30-fold promotion of S. aureus adhesion by platelets (in the presence of plasma, P = .0003) and a 5-fold promotion by plasma (in the presence of platelets, P = .0095). SEM of platelet-coated coverslips incubated with S. aureus in the presence of plasma showed large numbers of microorganisms, most forming aggregates and preferentially adherent to platelets but also, to a lesser extent, to the free substrate ( figure 2C) .
To test the possibility that promotion of S. aureus adhesion is largely due to S. aureus-S. aureus interaction in the presence of "clumping factors" contained in plasma, experiments were done in the absence of soluble plasma ligands. Coverslips with adherent platelets were pretreated with plasma for 15 min, washed, and incubated with S. aureus. With diluted (1 %) or undiluted (100%) plasma, the fold-increase of adhesion to plasma-treated over untreated platelets was 2.2 ± 0.6 (n = 3) or 2.0 ± 0.8 (n = 5), respectively. Thus, pretreatment of platelets with plasma enhanced S. aureus adhesion, although to a lesser extent than did coincubation of platelets, plasma, and S. aureus.
Plasma-enhanced adhesion was found to be sensitive to trypsin treatment of the microorganisms. S. aureus cells were pretreated with trypsin (1 mgjmL) for 30 min at 37°C and then with trypsin inhibitor (2 mgjmL) for 15 min at 37°C, JID 1993;167 (February) Figure 2 . Adhesion of S. aureus to albumin-and platelet-coated polymethylmethacrylate (PMMA). PMMA coverslips were prepared for S. aureus adhesion and scanning electron microscopy as described in Methods. A, Adhesion to uncoated PMMA. One adherent microorganism (arrow) is shown. Bar, 3 1Lm. B, S. aureus adhesion to platelet-coated coverslips in absence ofplasma proteins. Platelets (1 .5 X 10 5 /rnm") were allowed to adhere and spread on surfaces and were incubated with S. aureus in Tyrode's buffer containing human albumin. Staphylococci adhere both to platelets and to PMMA substrate. Bar. 3 1Lm. C, S. aureus adhesion to platelet-coated coverslips in presence of plasma. Large clusters of microorganisms adhere to surface, preferentially to spread adherent platelets or to fibrils. Bar, 2 1Lm. D, S. aureus adhesion to thrombin-stimulated platelets in presence of plasma. Large aggregates of microorganisms associated with fibrillar structures adhere to platelet-coated surfaces. Bar. 3 1Lm. E, F, Effect of anti-GPIIb/llla monoclonal antibodies (MAbs) on platelet spreading on poly-t-lysine (PLL)-coated PMMA and subsequent S. aureus adhesion. Platelets were incubated in Tyrodc's buffer without antibodies (E) or in buffer containing MAb IOE5 (F) as described in Methods. Platelets were then allowed to adhere to PMMA precoated with PLL, unbound antibodies were removed. and coverslips were incubated with S. aureus. Bar, 3 1Lm. E , Singular and aggregated microorganisms adhering to spread platelets. F, Most platelets remain in discoid or early pseudopodial stages with few platelets beginning to spread ; no adherent microorganisms are visible. none of the MAbs inhibited S. aureus adhesion if they were added to PMMA coverslips after platelet adhesion (data not shown). Therefore, platelets were preincubated with MAbs in suspension for 15 min at ambient temperature and allowed to adhere and then were washed in Tyrode's buffer containing antibodies. Thereafter, unbound antibodies were removed, and coverslips were transferred into buffer containing plasma and radiolabeled S. aureus. As shown in table I, MAbs IOE5, 7E3, and AP2 directed against the platelet OPIIb/IIIa complex were highly effective in inhibiting plasma-enhanced staphylococcal adhesion to platelet-coated surfaces whereas antibodies directed against other platelet glycoproteins and matrix proteins did not show a significant inhibitory effect. Conceivably, treatment of platelets with MAbs may result in decreased platelet adhesion to the substrate, diminished platelet spreading and activation, modifiwashed, and tested for adhesion in parallel with untreated S. aureus. Trypsinization decreased adhesion significantly (28.9% ± 11.0% of adhesion of untreated S. aureus, n = 9; P = .0007, unpaired t test).
The experimental conditions were analyzed using different platelet and plasma concentrations and incubation times. S. aureus adhesion was found to be a function of the number of platelets in the solution deposited on the coverslips for platelet adherence, and platelet numbers >50,000/ JLL were sufficient to maximally promote adhesion. Videoenhanced light microscopy revealed that at this platelet concentration >50% of the surface was covered with spread platelets. Furthermore, the optimal concentration of plasma for supplementing the adhesion assay plateaued at 1% (vol/ vol); concentrations of>5% (vol/vol) frequently resulted in clot formation in the test tube. Finally, adhesion increased as a function of incubation time, reaching a maximum after 45 min.
Effect of platelet activation on staphylococcal adhesion to platelet-coated surfaces. Solid surfaces may activate platelets in a manner similar to that of soluble agonists or of certain microorganisms, resulting in platelet spreading and aggregation [14] ; POE., an adenylate cyclase stimulant, inhibits platelet activation [40] . Platelets purified in the presence of POE, were allowed to adhere to coverslips washed with Tyrode's buffer with or without supplementation of thrombin (1 IU/mL) and then were tested for S. aureus adhesion. As shown in figure 3 , inhibition of platelet activation by POE, significantly decreased staphylococcal adhesion compared to controls (6.2% ± 4.4%, mean adhesion ± SE, n = 3, vs. 30.2% ± 5.3%, n = 14; P = .0438, Mann-Whitney test). Microscopic observation of POE,-treated platelets revealed that a number similar to control platelets adhered to the substrate; however, these platelets remained in the pseudopodial state after attachment, with only small numbers of bacteria adherent to the surfaces. This effect ofPOE, could readily be overcome by thrombin stimulation after platelet adherence. POE,-treated and subsequently thrombin-stimulated platelets were fully spread (figure 20), resulting in significant increase of adhesion (46.9% ± 7.2%, mean ± SE, n = 7; P = .0304 [Mann-Whitney test] vs. POEt-treated platelets without thrombin; figure 3 ). Staphylococcal adhesion was dosedependently stimulated by thrombin, with optimal adhesion at concentrations of 1 IU of thrombin, whereas AOP at even higher concentrations (10-3 M) failed to significantly promote adhesion ( figure 3) .
Effect ofanti-platelet surface antigen antibodies on staphylococcal adhesion. To examine more closely the ligands active in platelet-plasma-So aureus interactions, gel-purified platelets were preincubated with antibodies directed against either platelet integrins or extracellular matrix proteins that are possibly expressed on the platelet surface. Parallel experiments were done using control antibodies for the different classes of test antibodies. Initial experiments showed that cations of the interaction of platelet glycoproteins with plasma proteins or S. aureus or both, or a combination of these effects. Therefore, we first determined the number of platelets treated with MAb IOE5 that were adherent to PMMA using interference-based contrast microscopy and found that in fact the number was largely reduced (mean reduction of the number of IOE5-treated platelets vs. untreated platelets, 86.2% ± 1.1%). To reduce the effect of MAbs on platelet adhesion, PMMA coverslips were coated with PLL and then washed with Tyrode's buffer before platelets were added. Use ofPLL-coated coverslips allowed a similar number of platelets treated with IOE5 or AP2 to adhere compared with untreated platelets as determined by phasecontrast microscopy (mean reduction of the number of adherent platelet, 7.9% and 18.9% for IOE5-and AP2-treated platelets, respectively, compared with untreated platelets, n = 3). Subsequently, the effect of IOE5, 7E3, and AP2 on S. aureus adhesion was determined on PLL-coated PMMA. As shown in table I, S. aureus adhesion was also significantly inhibited by antibodies IOE5, 7E3, and AP2 on PLL-coated PMMA; therefore, the inhibitory effect of these antibodies was not due to changes in the number of platelets attached. To determine the effect of MAb IOE5 on platelet spreading on PLL-coated coverslips, additional samples were examined by SEM. Untreated platelets spread and promoted adhesion of the microorganisms (figure 2E) whereas IOE5-treated platelets adhered to the substrate but remained in a round or pseudopodiaI state and adhesion ofbacteria was not promoted ( figure 2F) .
Factors contained in plasma that promote S. aureus adhesion to platelet-coated surfaces. To remove or alter plasma constitutents, ACD-anticoagulated plasma was dialyzed overnight against PBS, passed through 0.2-J,Lm filter membranes, heat-treated (56°C, 30 min), clotted after supplementing with Ca 2 + , or treated with heparin-anticoagulated plasma; adhesion was also studied in the presence either of PPACK (final concentration, 1 J,LM), or of PMSF (final concentration, I mM) or in Tyrode's buffer without Ca 2 +. Experiments were done using either contact-or thrombin-activated platelets, and adhesion in the presence of pretreated or PPACK-or PMSF-supplemented plasma was compared with adhesion in the presence of whole ACD-anticoagulated plasma (control, figure 4) . Whereas dialysis or filtration of plasma had no significant effect on S. aureus adhesion, heat treatment, clotting, and heparin anticoagulation significantly decreased plasma-promoted adhesion. Furthermore, addition of PPACK or PMSF or Ca 2 +-free conditions resulted in significantly decreased adhesion (analysis of variance, P = .0001; Fisher's protected least significant difference, P < .01) except for the effect of PMSF on thrombinactivated platelets, which was not statistically significant. In addition to these experiments, adhesion assays containing plasma were supplemented either with polyclonal antibodies directed against fibrinogen or fibronectin or with control antibodies and incubated for 15 min prior to addition ofplate letcoated PMMA. As shown in table 2, antibodies directed against fibrinogen significantly inhibited S. aureus adhesion whereas antifibronectin or control antibodies were not active.
As another approach, purified plasma proteins, that is, fibrinogen, fibronectin, vitronectin, thrombospondin (each at 80 J,Lg/mL), or a mixture of fibrinogen, fibronectin, and thrombospondin, were substituted for whole plasma. On thrombin-activated platelets, fibrinogen promoted adhesion 3.2 ± 0.7-fold, the combination of fibrinogen, thrombospondin and fibronectin promoted adhesion 5.3 ± 0.8-fold, and Cohn plasma fraction I containing fibronectin and fibrinogen promoted adhesion 6.7-± l.O-fold (analysis of variance, P = .0001; Fisher's protected least significant difference, P < .01) compared with adhesion without plasma proteins. In contrast, adhesion to contact-activated platelets was enhanced only by whole plasma whereas the purified proteins, 
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including fibrinogen, failed to promote adhesion. Thus, other yet-not-identified factors contained in plasma are contributing to S. aureus adhesion to contact-activated platelets.
Discussion
Initial adherence of platelets occurs rapidly after contact with artificial surfaces or subendothelial cell matrix [14] followed by a platelet change from the discoid form to pseudopodial and ultimately irreversibly spread form on the surface [41] . Adherence also results in activation of the GPIIb/IIIa complex to recognize fibrinogen receptor migration central towards the granulomere [38] , a rise of intracellular calcium similar to that observed after thrombin stimulation ofsuspension platelets [42] , and a release of storage granule products such as fibrinogen, thrombospondin, and ADP [42] . Staphylococci have been shown to bind to suspension platelets; however, the major changes platelets undergo upon adhesion may modify their interaction with bacteria. Our experi- ments demonstrated that adhesion of S. aureus was enhanced --30-fold by adherent platelets. SEM revealed that microorganisms adhered both to the platelets and to the surrounding substrate. Artificial surfaces may preferentially adsorb fibrinogen [43] , and platelet-released proteins such as fibrinogen and thrombospondin may be deposited onto the PMMA surface, supporting subsequent staphylococcal adhesion.
In vivo, adhesion occurs in the presence of plasma factors that may act as bridging molecules between cellular receptors and staphylococcal adhesions as shown for the mediation of S. aureus adhesion to endothelial cells by fibrinogen [44] . Therefore, we examined staphylococcal adhesion in the presence of plasma proteins. Plasma extensively enhanced staphylococcal adhesion to platelet-coated PMMA but not to uncoated PMMA, suggesting that plasma proteins promote S. aureus adhesion by bridging adhesion-like molecules on both bacterial and platelet surfaces. Experiments with plasma-pretreated platelets and SEM observations suggest that in addition to direct S. aureus-platelet interaction, the extensive promotion ofadhesion in the presence of plasma is partly due to S. aureus-S. aureus interactions, or clumping. However, clumping as observed on fixed samples may also be due to the active centripetal movement of staphylococci over the platelet membrane and subsequent accumulation over the granulomere as revealed by real-time differential-interference contrast light microscopy of unfixed samples (unpublished data).
The observation that adherent platelets and plasma greatly increase S. aureus adhesion to PMMA warranted further investigation of the nature of ligands and receptors involved in these interactions. Using specific antibodies and purified plasma proteins, we separately assessed the role of receptors or proteins expressed on platelets or deposited on the PMMA substrate or both and of plasma ligands poten-lID 1993;167 (February) tially serving as bridging molecules between S. aureus and platelet-coated surfaces.
A family of cell-adhesion receptors termed integrins has been implicated in a variety of cell-cell and cell-matrix interactions. Members of the integrin family found on platelets include the GPIIb/lIIa (alIb/(33) receptor recognizing fibrinogen, GPIb/IX recognizing von Willebrand's factor, GPIc/I1a (as/{3,) recognizing fibronectin, GPIa/IIa (a2/{3,) recognizing collagen, and aV/{33 receptor recognizing vitronectin [45] . While S. aureusIllay bind directly to platelet membrane glycoproteins, a more likely possibility is that interaction ofS. aureus with platelet integrin occurs via matrix proteins because S. aureus possess binding sites for these ligands. MAbs directed against GPIIb/lIIa inhibited not only staphylococcal adhesion but also adherence of the pretreated platelets to the surfaces. By precoating PMMA with PLL, antiGPIIb/IIIa-treated platelets adhered in similar numbers compared with untreated platelets. However, SEM revealed that platelets treated with MAbs did not fully spread on the surfaces. Therefore, it is conceivable that anti-GPIIb/IIIadirected MAbs inhibit S. aureus adhesion to platelets by interfering with platelet spreading after adhesion of the platelets to the substrate; however, a direct effect of these MAbs on interaction of GPIIb/lIIa with fibrinogen also seems possible. In contrast to the GPIIb/IIla-directed antibodies, antibodies against fibrinogen, fibronectin, and thrombospondin, which may be expressed on the platelet membranes or adsorbed on the PMMA substrate, showed no significant inhibitory effect on staphylococcal adhesion.
Binding of fibrinogen to the GPIIb/IIla complex requires platelet activation and a conformational change of the integrin into an active state that recognizes, besides fibrinogen, other adhesive proteins such as von Willebrand's factor, fibronectin, vitronectin [45] , and thrombospondin [46] . Platelets can be activated by a number of stimuli such as attachment to solid matrices, ADP, and thrombin. This activation can be inhibited by agents that stimulate adenylate cyclase, such as PGE, [40] . Contact activation of platelets attaching to PMMA can be partially blocked by adding PGE" which reduces intracellular Ca2+ mobilization upon contact with PMMA, inhibits platelet activation and aggregation [42] , and may interfere with fibrinogen binding to GPIIb/lIIa [47] . In our assay, PG E, down-regulation of platelets correlated with decreased S. aureus adhesion. While a weak agonist such as ADP [48] did not overcome this PGE,-modulated down-regulation, thrombin, a strong agonist [48] , did reverse the PGE, effect. Taken together, these findings suggest that S. aureus adhesion to adherent platelets is dependent on platelet activation, that platelet adhesion to PMMA stimulates platelets sufficiently to promote subsequent S. aureus adhesion in the absence of inhibitors, and that S. aureus adhesion might be mediated via an activation of the GPIIb/lIIa complex [49] .
The following lines of evidence suggest that activation of clotting factors and fibrin formation play a major role in plasma-enhanced S. aureus adhesion to immobilized platelets. Whereas fibrinogen alone did not promote adhesion to contact-activated platelets, fibrinogen promoted S. aureus adhesion to thrombin-stimulated platelets, and it is possible that small amounts of thrombin present on the platelet surfaces after activation may initiate fibrin polymerization. Plasma-enhanced adhesion ofS. aureus was sensitive to antifibrinogen antibodies. Adhesion was inhibited in the presence of the specific thrombin antagonist PPACK, the serine proteinase inhibitor PMSF, or heparin, which induces inhibition ofcoagulation serine proteases including thrombin [50] . Adhering microorganisms were often associated with fibrillar structures visualized by SEM ( figure 2C, D) and supposedly consisting of fibrin. These findings concur with those described by others who examined platelet-bacteria interaction in suspension. Fibrinogen but not fibronectin was found to be a cofactor necessary for platelet aggregation after contact with S. aureus [9] or streptococci [11]; however, additional, unidentified plasma components were necessary to elicit maximal aggregation [11] . Taken together, these findings suggest that both bacteria-induced platelet aggregation and bacterial adhesion to immobilized platelets might require similar plasma-contained factors, that is, fibrinogen/fibrin serving as bridging molecules between bacteria and specific receptors on platelets such as the activated GPIIbjlIIa complex. This study describes for the first time the extensive promotion ofS. aureus adhesion to surfaces by adherent platelets in the presence of plasma and further supports the role of platelets in endocarditis or device-associated bloodstream infections. The complexity of the system, including the different ligands and receptors involved on platelets, in plasma, and on staphylococci, does not allow at this point the complete delineation of the mode of interaction of all the molecules involved; however, our results implicate platelet integrins and plasma fibrinogen/fibrin as important in the adhesion process ofS. aureus to platelets. Because adhesion is a prerequisite event for colonization and subsequent infection, these findings provide further understanding of the early pathogenic mechanisms of endovascular infections and may ultimately contribute to the development ofstrategies to prevent invasive infections due to S. aureus.
